The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma

Clinical Cancer Research

Volumn 13, Issue 24, 2007, Pages 7228-7231

  Wang, Ena ^a   Selleri, Silvia ^a   Marincola, Francesco M ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CLINICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LEUKOCYTE ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR ANTIGEN;

ARTICLE; AUTOIMMUNITY; CANCER GROWTH; CELL ACTIVATION; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL DIFFERENTIATION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 37549046415     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2150     Document Type: Article

References (25)

1. Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989;170:797-810.
2. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
3. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother 1996;19:266-77.
4. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going? J Natl Cancer Inst 2002;94:805-18.
5. Slingluff CL, Jr., Speiser DE. Progress and controversies in developing cancer vaccines. J Transl Med 2005;3:18.
6. Panelli MC, Riker A, Kammula US, et al. Expansion of Tumor-T cell pairs from Fine Needle Aspirates of Melanoma Metastases. J Immunol 2000;164:495-504.
7. Marincola FM, Ferrone S. Immunotherapy of melanoma: the good news, the bad news and what to do next. Semin Cancer Biol 2003;13:387-9.
8. Monsurro' V, Wang E, Panelli MC, et al. Active-specific immunization against melanoma: is the problem at the receiving end? Semin Cancer Biol 2003;13:473-80.
9. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet 2007.
10. Panelli MC, Wang E, Phan G, et al. Genetic profiling of peripheral mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol 2002;3:RESEARCH0035.
11. Panelli MC, Stashower M, Slade HB, et al. Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2006;8:R8.
12. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003;349:125-38.
13. Monsurro' V, Wang E, Yamano Y, et al. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004;104:1970-8.
14. Eichler W, Ruschpler P, Wobus M, Drossler K. Differentially induced expression of C-type lectins in activated lymphocytes. J Cell Biochem 2001;81:201-8.
15. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007;7:737-44.
16. Maccalli C, Nonaka D, Piris A, et al. NKG2D-mediated anti-tumor activity by TILs and antige-specific T cell clones isolated from melanoma patients. Clin Cancer Res 2007;13:7459-68.
17. Mandruzzato S, Callegaro A, Turcatel G, et al. A gene expression signature associated with survival in metastatic melanoma. J Transl Med 2006;4:50.
18. Wang E, Panelli MC, Zavaglia K, et al. Melanoma-restricted genes. J Transl Med 2004;2:34.
19. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002;111:837-51.
20. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-34.
21. Peixoto A, Evaristo C, Munitic I, et al. CD8 single-cell gene coexpression reveals three different effector types present at distinct phases of the immune response. J Exp Med 2007;204:1193-205.
22. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
23. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
24. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
25. Jin P, Wang E, Provenzano M, et al. Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med 2006;4:26.